Vanda Pharmaceuticals Revenue 2006-2021 | VNDA

Vanda Pharmaceuticals revenue from 2006 to 2021. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Vanda Pharmaceuticals Annual Revenue
(Millions of US $)
2020 $248
2019 $227
2018 $193
2017 $165
2016 $146
2015 $110
2014 $50
2013 $34
2012 $33
2011 $31
2010 $36
2009 $5
2008 $
2007 $
2006 $
2005 $
Vanda Pharmaceuticals Quarterly Revenue
(Millions of US $)
2021-06-30 $68
2021-03-31 $63
2020-12-31 $68
2020-09-30 $60
2020-06-30 $62
2020-03-31 $58
2019-12-31 $61
2019-09-30 $59
2019-06-30 $59
2019-03-31 $48
2018-12-31 $53
2018-09-30 $49
2018-06-30 $47
2018-03-31 $44
2017-12-31 $44
2017-09-30 $41
2017-06-30 $42
2017-03-31 $37
2016-12-31 $38
2016-09-30 $38
2016-06-30 $36
2016-03-31 $33
2015-12-31 $32
2015-09-30 $28
2015-06-30 $28
2015-03-31 $22
2014-12-31 $15
2014-09-30 $15
2014-06-30 $11
2014-03-31 $9
2013-12-31 $9
2013-09-30 $9
2013-06-30 $8
2013-03-31 $8
2012-12-31 $8
2012-09-30 $8
2012-06-30 $8
2012-03-31 $8
2011-12-31 $8
2011-09-30 $8
2011-06-30 $7
2011-03-31 $8
2010-12-31 $8
2010-09-30 $7
2010-06-30 $8
2010-03-31 $12
2009-12-31
2009-09-30
2009-06-30
2009-03-31
2008-12-31
2008-09-30
2008-06-30
2008-03-31
2007-12-31
2007-09-30
2007-06-30
2007-03-31
2006-12-31
2006-09-30
2006-06-30
2006-03-31
2005-12-31
2005-09-30
2005-06-30
2005-03-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.024B $0.248B
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics & genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. The Company has three product candidates in clinical development. It's lead product candidate, iloperidone, is a compound for the treatment of schizophrenia & bipolar disorder & is in a Phase III clinical trial for schizophrenia. It's second product candidate, is a compound for the treatment of insomnia & depression which is currently in a Phase III clinical trial for insomnia. It's third product candidate, is a compound for the treatment of excessive sleepiness & is ready for a Phase II clinical trial.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00